BLBAUPOST GROUP LLC/MA
Institutional investor · Portfolio as of Q4 2018
Top Holdings37 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 51.3M | $2.5B | 21.4% | — | — | 1 qtr | New 99 | |
CHENIERE ENERGY INC | 14.2M | $840.3M | 7.3% | $55.26 | 0.00% | 1 qtr | New 99 |
| 17M | $814.2M | 7.1% | $10.64 | +211.75% | 1 qtr | New 99 | |
VIASAT INC | 13.7M | $809.5M | 7.0% | $58.03 | 0.00% | 1 qtr | New 99 |
QORVO INC | 10.7M | $648.7M | 5.6% | $60.79 | 0.00% | 1 qtr | New 98 |
ALLERGAN PLC | 4.8M | $635.6M | 5.5% | — | — | 1 qtr | New 98 |
LIBERTY GLOBAL PLC | 29.7M | $613.9M | 5.3% | — | — | 1 qtr | New 98 |
PIONEER NATURAL RESOURCE | 4.5M | $591.8M | 5.1% | — | — | 1 qtr | New 98 |
EBAY INC | 21M | $589.5M | 5.1% | $25.13 | 0.00% | 1 qtr | New 98 |
P G & E CORP | 15.5M | $367.5M | 3.2% | $23.62 | 0.00% | 1 qtr | New 87 |
| 300M | $364.1M | 3.2% | — | — | — | New 87 | |
SYNCHRONY FINANCIAL | 14.6M | $341.4M | 3.0% | $19.63 | 0.00% | 1 qtr | New 81 |
ANTERO RESOURCES CORP | 28.6M | $268.4M | 2.3% | $9.21 | 0.00% | 1 qtr | New 81 |
THERAVANCE BIOPHARMA INC | 9.3M | $238.2M | 2.1% | $23.43 | 0.00% | 1 qtr | New 80 |
COLONY CAP INC NEW | 49.7M | $232.5M | 2.0% | — | — | 1 qtr | New 80 |
Atara Biotherapeutics, Inc. | 6.3M | $217.3M | 1.9% | — | — | — | — |
MCKESSON CORP | 1.7M | $190M | 1.6% | $104.44 | 0.00% | 1 qtr | New 71 |
UNIVAR INC | 9.5M | $168.5M | 1.5% | — | — | 1 qtr | New 70 |
AMERISOURCEBERGEN CORP | 2M | $149.9M | 1.3% | $57.70 | 0.00% | 1 qtr | New 70 |
AKEBIA THREAPEUTICS INC | 24.5M | $135.3M | 1.2% | $5.39 | 0.00% | 1 qtr | New 70 |
BAUPOST GROUP LLC/MA manages $11.5B across 37 positions as of Q4 2018. Top holdings: NWS/A (21.4%), LNG (7.3%), NWS (7.1%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 3/5.0.
Active quarter - 37 new positions, 0 exits, 0 increased. Top move: NWS/A (NEW, conviction 99). Portfolio: $11.5B across 37 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer